In patients with hypertension who are at high risk for cardiovascular (CV) events, is long-acting nifedipine, a calcium-channel blocker, as effective as co-amilozide (hydrochlorothiazide and amiloride) for preventing CV and cerebrovascular mortality and morbidity?
D e s i g n
Randomized (allocation concealed*), blinded (patients, physicians, and outcome assessors),* placebo-controlled trial with ≥
3-year follow-up (Intervention as a Goal in Hypertension Treatment [INSIGHT] trial).

S e t t i n g
703 centers in 8 countries in western Europe and Israel.
P a t i e n t s
7343 patients with hypertension were enrolled, 6575 were randomized, and 6321 (mean age 65 y, 54% women) were studied after exclusion of 9 centers because of protocol violations. Patients were required to have ≥ 1 additional CV risk factor (hypercholesterolemia, smoking, family history of early myocardial infarction [MI] , left ventricular hypertrophy or strain, coronary artery disease, or peripheral vascular disease). Follow-up was 94%.
I n t e r v e n t i o n 3157 patients were analyzed in the longacting nifedipine group (30 mg/d), and 3164 were in the co-amilozide group (hydrochlorothiazide, 25 mg/d, and amiloride, 2.5 mg/d). If hypertension persisted, the regimen was intensified in steps that included doubling the dose of the study drug; adding atenolol, 25 mg/d, or enalapril, 5 mg/d; doubling the dose of the second drug; and adding another antihypertensive drug other than a calciumchannel blocker or diuretic.
M a i n o u t c o m e m e a s u r e s
A composite end point of CV or cerebrovascular death and nonfatal MI, stroke, and heart failure. Secondary outcomes were all-cause mortality, vascular death, and nonfatal vascular events.
M a i n r e s u l t s
Blood pressure (BP) decreased in both groups to approximately 138/82 mm Hg. Nonfatal heart failure was more common in the nifedipine group than in the coamilozide group (0.8% vs 0.3%, P = 0.028) as were fatal MI (0.5% vs 0.2%, P = 0.017) and all adverse events (49% vs 42%, P < 0.001). Withdrawals because of adverse effects were higher in the nifedipine group than in the co-amilozide group (23% vs 16%, P < 0.001). The groups did not differ for the primary outcomes, including the composite end point (6.3% in the nifedipine group vs 5.8% in the co-amilozide group, P = 0.35), all-cause (P = 0.95) or cause-specific mortality (P ≥ 0.14), nonfatal MI (P = 0.52), sudden death (P = 0.43), stroke (P ≥ 0.52), fatal heart failure (P = 0.63), or nonfatal CV events (P ≥ 0.1).
C o n c l u s i o n s
Nifedipine and co-amilozide were equally effective for preventing cardiovascular and cerebrovascular mortality and morbidity in high-risk patients with hypertension. Fewer patients, however, tolerated nifedipine. • None were large enough to reliably detect moderate differences (10% to 15%) in such clinically important outcomes as MI (1).
• BP control with monotherapy was not achieved in as many as one third to one half of trial participants, depending on baseline and target BP levels.
• Comparisons among agents were usually complicated by the addition of second and third drugs.
• In large trials, such as INSIGHT and the Swedish Trial in Old Patients (STOP-2) (2), a third or more of the participants were withdrawn from their initially assigned regimens because of adverse effects, difficulty with adherence to long-term therapy, or both.
• Occasional findings within trials, such as more fatal MI and nonfatal heart failure with calcium antagonists in the INSIGHT trial and fewer strokes with calcium antagonists in the NORDIL study, may result from chance because several comparisons were usually done.
• Intermediate and long-acting nondihydropyridine and dihydropyridine calcium antagonists were being evaluated. Clinicians are rightfully wary of generalizing beneficial and harmful class effects across these agents.
• Calcium antagonists are being compared with different agents within different classes. Clinicians realize that simple conclusions about calcium antagonists compared with "all other" agents are unlikely.
• Some trials, such as NORDIL, do not achieve equivalence in BP lowering among calcium antagonists and other agents.
(continued on page 7)
In middle-aged patients with hypertension, is diltiazem, a nondihydropyridine calcium antagonist, as effective as diuretics, β-blockers, or both at preventing cardio- 
S e t t i n g
1032 primary health care centers in Norway and Sweden.
P a t i e n t s
10 881 patients (mean age 60 y, 51% women) who had hypertension (diastolic blood pressure [BP] ≥ 100 mm Hg on 2 occasions) and were aged 50 to 69 years (extended to 74 y during the study). Follow-up was > 99%.
I n t e r v e n t i o n
Patients were allocated to diltiazem (n = 5410) or to diuretics or β-blockers, or both (n = 5471). If hypertension persisted, the regimen was intensified. Diltiazem was started at 180 to 360 mg/d, with stepped addition of an angiotensin-converting enzyme (ACE) inhibitor, a diuretic or α-blocker, and any other antihypertensive drug. In the other group, a thiazide diuretic or β-blocker was started with stepped addition of the other drug, an ACE inhibitor or α-blocker, and any other antihypertensive drug except a calcium antagonist.
M a i n o u t c o m e m e a s u r e s
BP and combined fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (MI), and other CV death.
M a i n r e s u l t s
Mean BP decreased in both groups, to 155/89 in the diltiazem group and to 152/89 mm Hg in the diuretics and β-blocker group. For patients who remained in the study for ≥ 24 months, decreases in systolic but not diastolic BP were smaller in the diltiazem group than in the diuretics and β-blocker group (20/19 vs 23/19 mm Hg, P < 0.001). The groups did not differ for the combined primary end point (16.6 vs 16.2 events/1000 patient-y, P = 0.97), all MI (7.4 vs 6.3, P = 0.17), CV death (5.2 vs 4.5, P = 0.41), all-cause mortality (9.2 vs 9.0, P = 0.99), all cardiac events (20.2 vs 19.2, P = 0.57), diabetes mellitus (9.4 vs 10.8, P = 0.14), and congestive heart failure (2.5 vs 2.1, P = 0.42).
Patients in the diltiazem group had fewer strokes than did patients in the diuretics and β-blocker group (6.4 vs 7.9 events/ 1000 patient-y, P = 0.04). The rate of adverse effects was similar among the groups.
C o n c l u s i o n
Diltiazem was as effective as diuretics, β-blockers, or both for preventing the combined end point of stroke, myocardial infarction, and other cardiovascular death.
Diltiazem was as effective as diuretics or β-blockers, or both, at preventing cardiovascular mortality and morbidity 
C o m m e n t a r y (continued from page 6)
Given these complexities, we clinicians can embrace the following "truths." We have no strong, consistent evidence that intermediate or long-acting calcium antagonists are superior or inferior to other antihypertensive agents in reducing CV disease and mortality. We have suggestive worrisome evidence that some intermediate and long-acting calcium antagonists may increase such cardiac harms as MI and heart failure more than do diuretics (INSIGHT trial) or ACE inhibitors (2) (3) (4) (5) . We know that adverse effects of antihypertensive therapies vary. For example, peripheral edema is reported by as many as 25% of persons taking calcium antagonists (INSIGHT trial) (2), and cough is reported by as many as 30% of those taking ACE inhibitors (2) . We know calcium antagonists are often more expensive than other antihypertensive agents. While we await results of additional large, longterm trials, many evidence-based clinicians will continue to choose agents other than calcium antagonists as first-line therapy for patients with hypertension.
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